Wednesday, 22 July 2009

More oral amphotericin developments

Old dog (new trick?)
We featured a story a few months back which was based on the development of a variant of amphotericin which could be taken by mouth rather than as now by intravenous injection (IV). There are a number of advantages to taking a drug orally, not the least of which is convenience for the patient (they can administer their own drug at home) but also includes reducing the number of visits to hospital as IV has to be done under close medical supervision.

It turns out that there is more than one oral amphotericin drug under test. This article mentions a drug currently known as iCo-009 which has already been extensively researched (though it looks like all of the currently published work is based on animal models) and found to be promising. Human trials are the next step.

There is more work to do before this or other new variants of amphotericin B comes to the clinic but these are hopeful signs of the development of new uses for older drugs which can only be a good thing for all concerned.

4 comments:

Anonymous said...

Until about 2 years ago there was a perfectly servicable amphoterracin Tablet (fungillin 50 mg) made by Squibb. I suspect they stopped it because it did not make money. No research needed, just prevail on someone to make a version of the above.

allergydoctor.org.uk

Website Team GA said...

Fungillin was primarily used for treatment of oral and gut infectons and was not useful for the treatment of systemic or invasive infection as it was poorly absorbed.
The new generation of drugs based on amphotericin is much more readily absorbed.

Anonymous said...

Has anyone had any experience with omalizumab for treating ABPA? There are case reports written by Jennifer Collins, MD & collegues.

Collins, Jennifer MD, Hudes, Golda, MD, PH.D and Rosenstriech, David MD. Allergic Bronchopulmonary Aspergillosis Treated Successfully with Omalizumab: Three Case Reports. Oral presentation; Annals of Allergy Asthma and Immunology. 2008;100(1 Suppl 1):A3-97.

Website Team GA said...

Omalizumab is in current use for a very specific subgroup of ABPA patients in the UK. It is expensive to prescribe and requires regular injections so not easy to administer, but in some cases works well.
It is hoped that an orally administered version will be developed at some point.

Amazon Contextual Product Ads

Contact us at admin@aspergillus.org.uk